Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Categories
Countries
MEDICAL CANNABIS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 121 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 121 pages
- Published: 04-08-2019
The global medical cannabis market size was estimated to reach a value of US$ 13.4 Billion in 2018. The market is further expected to reach value of US$ 44.4 Billion by 2024, exhibiting a CAGR of 22.9% during 2019-2024. Cannabis is a psychoactive drug which is derived from the cannabis plant of the Cannabaceae family. It has been used medicinally for several years in ancient Indian, Chinese, Egyptian and Islamic cultures. Nowadays, cannabis finds application in the treatment of a wide range of diseases and symptoms including cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, MS, AIDS, ALS, Alzheimer’s, PTSD, Parkinson’s, Tourette’s, etc. Owing to its therapeutic benefits, cannabis has been approved for medical use in numerous countries, with varying degrees of legal restriction. Some of these countries include Argentina, Brazil, Canada, Chile, Colombia, Czech Republic, Germany, Italy, Mexico, Spain, United Kingdom, United States, Uruguay, etc.
Global Medical Cannabis Market Drivers:
Cannabis is safer and has less severe side effects in comparison to other treatment options. It also finds usage along with other treatments either to enhance their effect or to combat negative side effects. For instance, cannabis is very effective in reducing nausea and increasing appetite among the chemotherapy patients, making the agonizing treatment more tolerable. Similarly, it is also used in combination with traditional opioid painkillers, which enables patients to significantly reduce the dosage and frequency of opioids, and also imparts greater pain relief.
A steadily rising ageing population has also played an significant role in driving the demand for medical cannabis as geriatric patients are more likely to develop chronic illnesses and require more physician visits.
Clinical trials, R&D activities and commercialization of cannabis-based indications are further expected to catalyze the growth of the market.
Although expenditure on health products are less susceptible to fluctuations in consumer’s expenditure, the uptake of medical marijuana is liable to changes in disposable income due to its unconventional nature. As a result, we expect increasing disposable incomes to create a positive impact on the demand of medical cannabis.
Breakup by Species:
On the basis of species, the market has been segmented as Indica, Sativa and hybrid. Currently, Indica dominates the market, holding the largest share. It is often used in the treatment of insomnia, relaxing the muscles, relieving body pains, headaches and migraines.
Breakup by Derivatives:
Based on derivatives, the market has been divided into Cannabidiol (CBD), Tetrahydrocannabinol (THC) and others. CBD is majorly used for medical purposes due to its non-psychotic effect and low levels of toxicity, whereas, THC is utilised to reduce the side-effects of AIDS and cancer treatment.
Breakup by Application:
The market has also been divided on the basis of application, wherein, cancer represents the leading category. Other major applications of cannabis include arthritis, migraine, epilepsy, etc.
Breakup by End-Use:
On the basis of end-use, the market has been segregated into the pharmaceutical industry, research and development centers, and others. Currently, the pharmaceutical industry represents the biggest end-user.
Breakup by Route of Administration:
Based on route of administration, the market has been categorized into oral solutions and capsules, smoking, vaporizers, topicals and others. Oral solutions and capsules represent the biggest segment, accounting for the largest market share.
Regional Insights:
On a geographical front, North America enjoys the leading position in the market. Recent legalization of cannabis in North America for both recreational and medical purposes has been a major driver of the market growth. Other key regions include Europe, Asia Pacific, Latin America, and Middle East and Africa.
Competitive Landscape:
The report has also examined the competitive landscape of the market. Some of the major players include:
Canopy Growth Corporation
GW Pharmaceuticals
Aurora Cannabis, Inc.
Aphria Inc.
MedReleaf Corporation
Insys Therapeutics, Inc.
CanniMed Therapeutics, Inc.
Cara Therapeutics, Inc.
United cannabis Corporation
Key Questions Answered in This Report:
- How has the global medical cannabis market performed so far and how will it perform in the coming years?
- What are the key regions in the global medical cannabis market?
- Which are the popular species in the global medical cannabis market?
- What are the key derivatives in the global medical cannabis market?
- What are the various applications of medical cannabis?
- Who are the major end-user industries for medical cannabis?
- What are the major routes of administration in the global medical cannabis market?
- What are the various stages in the value chain of the medical cannabis industry?
- What are the key driving factors and challenges in the global medical cannabis industry?
- What is the structure of the global medical cannabis industry and who are the key players?
- What is the degree of competition in the global medical cannabis market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Medical Cannabis Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Species 5.4 Market Breakup by Derivative 5.5 Market Breakup by Application 5.6 Market Breakup by End-Use 5.7 Market Breakup by Route of Administration 5.8 Market Breakup by Region 5.9 Market Forecast 5.10 SWOT Analysis 5.10.1 Overview 5.10.2 Strengths 5.10.3 Weaknesses 5.10.4 Opportunities 5.10.5 Threats 5.11 Value Chain Analysis 5.11.1 Input Suppliers 5.11.2 Collectors 5.11.3 Manufacturers 5.11.4 Distributors 5.11.5 Exporters 5.11.6 Retailers 5.11.7 End-User 5.12 Porters Five Forces Analysis 5.12.1 Overview 5.12.2 Bargaining Power of Buyers 5.12.3 Bargaining Power of Suppliers 5.12.4 Degree of Competition 5.12.5 Threat of New Entrants 5.12.6 Threat of Substitutes 5.13 Key Success and Risk Factors 6 Market Breakup by Species 6.1 Indica 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Sativa 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Hybrid 6.3.1 Market Trends 6.3.2 Market Forecast 7 Market Breakup by Derivative 7.1 Cannabidiol (CBD) 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Tetrahydrocannabinol (THC) 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Others 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by Application 8.1 Cancer 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Arthritis 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Migraine 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Epilepsy 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Others 8.5.1 Market Trends 8.5.2 Market Forecast 9 Market Breakup by End-Use 9.1 Pharmaceutical Industry 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Research and Development Centres 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Others 9.3.1 Market Trends 9.3.2 Market Forecast 10 Market Breakup by Route of Administration 10.1 Oral Solutions and Capsules 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 Smoking 10.2.1 Market Trends 10.2.2 Market Forecast 10.3 Vaporizers 10.3.1 Market Trends 10.3.2 Market Forecast 10.4 Topicals 10.4.1 Market Trends 10.4.2 Market Forecast 10.5 Others 10.5.1 Market Trends 10.5.2 Market Forecast 11 Market Breakup by Region 11.1 North America 11.1.1 United States 11.1.1.1 Market Trends 11.1.1.2 Market Forecast 11.1.2 Canada 11.1.2.1 Market Trends 11.1.2.2 Market Forecast 11.2 Europe 11.2.1 Germany 11.2.1.1 Market Trends 11.2.1.2 Market Forecast 11.2.2 Italy 11.2.2.1 Market Trends 11.2.2.2 Market Forecast 11.2.3 France 11.2.3.1 Market Trends 11.2.3.2 Market Forecast 11.2.4 Netherlands 11.2.4.1 Market Trends 11.2.4.2 Market Forecast 11.2.5 Spain 11.2.5.1 Market Trends 11.2.5.2 Market Forecast 11.3 Latin America 11.3.1 Market Trends 11.3.2 Market Forecast 11.4 Asia Pacific 11.4.1 Market Trends 11.4.2 Market Forecast 11.5 Middle East and Africa 11.5.1 Market Trends 11.5.2 Market Forecast 12 Overview of Clinical Research Suggesting the Benefits of Medical Cannabis Across Various Indications 12.1 Alzheimer’s Disease 12.2 Autism 12.3 Cancer 12.4 Chronic Pain 12.5 Epilepsy 12.6 Migraine 12.7 Digestive Disorders 12.8 Multiple Sclerosis 12.9 Schizophrenia 12.10 Others 13 Competitive Landscape 13.1 Market Structure 13.2 Key Players 14 Key Player Profiles |
Market Breakup by Species
- Indica
- Sativa
- Hybrid
Market Breakup by Derivative
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
Market Breakup by Application
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
Market Breakup by End-Use
- Pharmaceutical Industry
- Research and Development Centres
- Others
Market Breakup by Route of Administration
- Oral Solutions and Capsules
- Smoking
- Vaporizers
- Topicals
- Others
Market Breakup by Region
- North America
- United States
- Canada
- Europe
- Germany
- Italy
- France
- Netherlands
- Spain
- Latin America
- Asia Pacific
- Middle East and Africa
JAPAN GENERIC DRUG MARKET: INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 98 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 98 pages
- Published: 04-08-2019
Japan represents the world’s eighth biggest market for generic drugs in terms of value. Generic drugs, however, have traditionally enjoyed a relatively lower penetration in Japan compared to other developed markets such as the United States and Europe. Historically, the lower penetration of generic drugs in japan was due to several reasons. These included – the perception of inferior quality of generic drugs, the preference of branded drugs among physicians and patients and the limited profits to be made by physicians from pharmaceutical price differentials by prescribing low priced generics. Generic drugs also remained less popular in Japan because of the lack of generic substitution rights by Japanese pharmacists, slower review times in the drug approval process and difficulties working with major pharmaceutical distributors – many of whom were closely tied to major branded drug manufacturers.
The landscape of the japan generic drug market, however, has changed noticeably over the last decade. The Japanese government has identified growth of the country’s generic drug market as imperative to Japan’s long-term economic health. The Japanese government, recognizing the country’s increasing aging population as well as rising costs of branded drugs has begun instituting healthcare policy changes to cut their expenditures on medical costs. Drug costs account for around a fifth of the country’s total medical expenses and reducing this burden has become a cornerstone of Japan’s health administration policy. Substitution of low-cost generic drugs for innovator products has been identified as a strategy where major savings are possible. Driven by these initiatives, the penetration of generics has grown robustly over the past few years. The government has also made a target towards achieving a generic penetration of 60% by 2018. This is expected to create huge opportunities for both domestic and foreign generic manufacturers in Japan.
The report entitled “Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” represents an in-depth analysis on the historical, current and future market trends in the generic drug market in Japan. This research report serves as an exceptional tool to understand the drivers, sales trends, prescription trends, market structure, competitive landscape, regulations, key players, key drugs, manufacturing and the outlook of generic drug market in Japan. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who want to gain an insight into the generic drug market in Japan.
Key Questions Answered:
- What are generic drugs? How are they different from branded drugs?
- How has Japan’s generic drug market performed in recent years?
- How have generic drugs performed compared to branded drugs?
- What were the total sales and prescriptions for generic drugs in Japan?
- Who are the key players in the Japanese generic drug market? How have they performed?
- What is the structure of the Japanese generic drug market?
- What is the pricing mechanism of generic drugs in Japan?
- What is the value chain of generic drugs in Japan?
- What are the regulations for generic drugs in Japan?
- How are generic drugs distributed in Japan?
- How are generic drugs manufactured?
- What are the raw material and machinery requirements to manufacture generic drugs?
- What are the drivers and challenges in the Japanese generic drug market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Japan Generic Drug Market – Introduction 4.1 What are Generic Drugs? 4.2 Unbranded and Branded Generic Drugs 4.3 Authorized Generic Drugs 5 Why is the Japanese Generic Drug Market So Lucrative 5.1 Blockbuster Drugs Going Off-Patent 5.2 Rising Healthcare Costs Coupled with an Increasing Ageing Population 5.3 Japan Has One of the Lowest Penetration of Generics 5.4 Incentives for Dispensing Generics 5.5 Significant Savings for Payers and Providers 5.6 Biosimilars 6 Global Generic Drug Market 6.1 Market Performance 6.1.1 Value Trends 6.1.2 Volume Trends 6.2 Market Breakup by Country 6.2.1 Market Breakup by Volume 6.2.2 Market Breakup by Value 6.3 Market Forecast 6.4 Most Prescribed Generic and Branded Drugs 7 Japan Generic Drug Market 7.1 Japan Pharmaceutical Market Performance 7.1.1 Value Trends 7.1.2 Volume Trends 7.1.3 Market Breakup by Type 7.1.4 Market Forecast 7.2 Japan Generic Drug Market Performance 7.2.1 Value Trends 7.2.2 Volume Trends 7.2.3 Market Forecast 8 SWOT Analysis 8.1 Overview 8.2 Strength 8.3 Weakness 8.4 Opportunities 8.5 Threats 9 Pricing Mechanism and Profit Margins at Various Levels of Supply Chain 10 Porter’s Five Forces Analysis 10.1 Overview 10.2 Bargaining Power of Buyers 10.3 Bargaining Power of Suppliers 10.4 Degree of Competition 10.5 Threat of New Entrants 10.6 Threat of Substitutes 11 Japan Generic Drug Market- Competitive Landscape 11.1 Japan Generic Drug Market – Competitive Structure 11.2 Japan Generic Drug Market – Breakup by Key Players 11.3 Japan Generic Drug Market – Breakup by Distribution Channel 12 Japan Generic Drug Market- Value Chain Analysis 12.1 Research and Development 12.2 Manufacturing 12.3 Marketing 12.4 Distribution 13 Regulations in Japan Generics Industry 13.1 Approval Pathway of a Generic Drug in Japan 13.1.1 Master File Scheme for Active Ingredients 13.1.2 Equivalency Review 13.1.3 Conformity Audit 13.2 Certifications 13.2.1 MAH (Market Authorization Holder) License for Product Approval 13.2.2 FMA (Foreign Manufacturer Accredited) Certification for Product Approval 13.2.3 DMF (Drug Master File) Registration 13.2.4 GMP (Good Manufacturing Practices) Certification 13.2.5 Manufacturer’s License 14 Japan Generic Drug Market: Key Success Factors 15 Japan Generic Drug Market: Road Blocks 16 Requirements for Setting up a Generic Drug Manufacturing Plant 16.1 Manufacturing Process 16.2 Raw Material Requirements 16.3 Raw Material Pictures 16.4 Land and Construction Requirements 16.5 Machinery and Infrastructure Requirements 16.6 Machinery Pictures 16.7 Plant Layout 16.8 Packaging Requirements 16.9 Utility Requirements 16.10 Manpower Requirements 17 Japan Generic Drug Market – Key Company Profiles |
Global Generic Drug Market
Japan Generic Drug Market
JAPAN DIABETES MARKET REPORT: 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 89 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 89 pages
- Published: 04-08-2019
The Japan diabetes market reached a value of more than US$ 4 Billion in 2018, registering a CAGR of 4.4% during 2011-2018. The market is further projected to cross US$ 5 Billion by 2024, growing at a CAGR of 3.8% during 2019-2024. Diabetes refers to a chronic disease in which the ability of a human body to produce and respond to insulin hormone becomes impaired. This results in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood. In Japan, a large section of the population is over 60 years, an age when type-2 diabetes becomes more prevalent. Moreover, as the Japanese diet consists of a significant portion of refined carbohydrates, like white rice and noodles, it puts the population at a higher risk of developing and aggravating diabetes.
Japan Diabetes Market Drivers:
With the growing influence of western cuisines, increasing working hours and declining domestic agricultural production, consumers are now relying on processed food products and fast-food like burger, taco, hotdog and pizza. As these food products are high in carbohydrates, sodium and preservatives, their rising consumption has increased the cases of diabetes in the country. The other factors that are contributing to the increasing cases of diabetes include growing obese population and sedentary lifestyles. However, to minimize the prevalence of diabetes in the country, the Government of Japan is undertaking several initiatives. For instance, it is offering health insurance to both the citizens and non-citizens residing for more than a year in Japan through their universal health care system.
Breakup by Segment:
Oral Antidiabetics
Insulin
Currently, insulin represents the dominant segment, accounting for the majority of the total market share. Insulin in Japan is usually taken through pens, pumps, syringes and jet injectors as they offer convenience to the patients. Increasing diagnostic rates and awareness among patients are enabling them to incorporate insulin therapy for treating diabetes.
Competitive Landscape:
The competitive landscape of the market has been analyzed in the report with detailed profiles of key players operative in the industry.
Key Questions Answered in This Report:
- How has the Japan diabetes market performed so far and how will it perform in the coming years?
- Which are the popular segments in the Japan diabetes market?
- What are the various stages in the value chain of the Japan diabetes market?
- What are the key driving factors and challenges in the Japan diabetes market?
- What is the structure of the Japan diabetes market and who are the key players?
- What is the degree of competition in the Japan diabetes market?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Diabetes Disease Overview 5.1 What is Diabetes? 5.2 Diabetes Diagnosis and Treatment 5.2.1 Diagnosis 5.2.2 Treatment 5.3 Diabetes Complications 6 Japan Diabetes Epidemiology 6.1 Diabetes Population and Prevalence Rates 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2) 6.3 Population and Prevalence Rates by Region 6.4 Population and Prevalence Rates by Gender 6.5 Population and Prevalence Rates by Age Group 7 Japan Diabetes Market 7.1 Market Overview 7.2 Market Performance 7.3 Market Forecast 7.4 SWOT Analysis 7.4.1 Overview 7.4.2 Strengths 7.4.3 Weaknesses 7.4.4 Opportunities 7.4.5 Threats 7.5 Value Chain Analysis 7.6 Porter’s Five Forces Analysis 7.6.1 Overview 7.6.2 Bargaining Power of Buyers 7.6.3 Bargaining Power of Suppliers 7.6.4 Degree of Competition 7.6.5 Threat of New Entrants 7.6.6 Threat of Substitutes 7.7 Market Breakup by Segment 7.7.1 Japan Oral Antidiabetics Market 7.7.1.1 Historical Market Trends 7.7.1.2 Market Breakup by Class 7.7.1.3 Market Shares of Key Players 7.7.1.4 Market Forecast 7.7.2 Japan Insulin Market 7.7.2.1 Historical Market Trends 7.7.2.2 Market Breakup by Class 7.7.2.3 Market Shares of Key Players 7.7.2.4 Market Forecast 8 Competitive Landscape 8.1 Competitive Structure 8.2 Profiles of Key Players |
Japan Diabetes Epidemiology
Japan Diabetes Market
HIV DRUGS MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 102 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 102 pages
- Published: 04-08-2019
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV virus, thereby reducing the risk of its transmission. According to the latest report by IMARC Group, titled “HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024”, the global HIV drugs market exceeded a value of US$ 24.7 Billion in 2018.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs. Looking forward, the market value is projected to reach US$ 22.5 Billion by 2024, declining at a CAGR of 2.5% during 2019-2024.
Market Summary:
Based on class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors – CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa, and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
The competitive landscape of the market has also been examined with some of the key players being Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson and Merck.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
Key Questions Answered in This Report:
- How has the global HIV drugs market performed so far and how will it perform in the coming years?
- What are the key regions in the global HIV drugs market?
- Which are the popular class types in the global HIV drugs market?
- What are the major distribution channels in the global HIV drugs market?
- What are the various stages in the value chain of the global HIV drugs market?
- What are the key driving factors and challenges in the global HIV drugs market?
- What is the structure of the global HIV drugs market and who are the key players?
- What is the degree of competition in the global HIV drugs market?
- How are HIV drugs manufactured?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global HIV Drugs Market 5.1 Market Overview 5.2 Market Performance 5.3 Price Analysis 5.4 Market Breakup by Drug Class 5.5 Market Breakup by Distribution Channel 5.6 Market Breakup by Region 5.7 Market Forecast 5.8 SWOT Analysis 5.8.1 Overview 5.8.2 Strengths 5.8.3 Weaknesses 5.8.4 Opportunities 5.8.5 Threats 5.9 Value Chain Analysis 5.9.1 Overview 5.9.2 Research and Development 5.9.3 Raw Material Procurement 5.9.4 Manufacturing 5.9.5 Marketing 5.9.6 Distribution 5.9.7 End-Use 5.10 Porters Five Forces Analysis 5.10.1 Overview 5.10.2 Bargaining Power of Buyers 5.10.3 Bargaining Power of Suppliers 5.10.4 Degree of Competition 5.10.5 Threat of New Entrants 5.10.6 Threat of Substitutes 6 Market Breakup by Drug Class 6.1 Nucleoside Reverse Transcriptase Inhibitors 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Multi-Class Combination Products 6.2.1 Market Trends 6.2.2 Market Forecast 6.3 Protease Inhibitors 6.3.1 Market Trends 6.3.2 Market Forecast 6.4 HIV Integrase Strand Transfer Inhibitors 6.4.1 Market Trends 6.4.2 Market Forecast 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors 6.5.1 Market Trends 6.5.2 Market Forecast 6.6 Entry Inhibitors — CCR5 Co-Receptor Antagonist 6.6.1 Market Trends 6.6.2 Market Forecast 6.7 Fusion Inhibitors and Others 6.7.1 Market Trends 6.7.2 Market Forecast 7 Market Breakup by Distribution Channel 7.1 Hospital Pharmacies 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Retail Pharmacies 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Online Pharmacies 7.3.1 Market Trends 7.3.2 Market Forecast 7.4 Others 7.4.1 Market Trends 7.4.2 Market Forecast 8 Market Breakup by Region 8.1 North America 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Europe 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Asia Pacific 8.3.1 Market Trends 8.3.2 Market Forecast 8.4 Middle East and Africa 8.4.1 Market Trends 8.4.2 Market Forecast 8.5 Latin America 8.5.1 Market Trends 8.5.2 Market Forecast 9 HIV Drugs Manufacturing Process 9.1 Product Overview 9.2 Raw Material Requirements 9.3 Manufacturing Process 9.4 Key Success and Risk Factors 10 Competitive Landscape 10.1 Market Structure 10.2 Market Breakup by Key Players 10.3 Profiles of Key Players 10.3.1 Boehringer Ingelheim International GmbH 10.3.2 Merck & Co., Inc. 10.3.3 ViiV Healthcare 10.3.4 AbbVie 10.3.5 F. Hoffmann-La Roche Ltd. 10.3.6 Teva Pharmaceutical Industries Ltd. 10.3.7 Bristol-Myers Squibb 10.3.8 Gilead Sciences, Inc. 10.3.9 Johnson & Johnson 10.3.10 Cipla Limited 10.3.11 Daiichi Sankyo 10.3.12 Emcure 10.3.13 Hetero Drugs 10.3.14 Mylan |
Market Breakup by Drug Class
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors and Others
- Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
HEMOGLOBIN TESTING MARKET: GLOBAL INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 109 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 109 pages
- Published: 04-08-2019
The global hemoglobin testing market was worth US$ 1.7 Billion in 2018. A hemoglobin test measures the count of red blood cells (RBC) or the level of hemoglobin in the blood. Hemoglobin is a type of protein present in the RBCs that carries oxygen to the organs and transports carbon dioxide back to the lungs. Hemoglobin tests are used extensively by doctors as a part of their routine check-ups or to diagnose a serious medical condition in the patient. If a test reveals that the hemoglobin level in an individual’s body is lower than normal, it means that they have a low RBC count and are prone to disorders such as anemia. If the RBC count is higher than normal, it could be an indication for a blood disorder or can be caused by living at a high altitude, smoking and dehydration. The key end users of hemoglobin testing market are medical laboratories, hospitals and research centers.
An increasing prevalence of chronic disorders such as anemia and diabetes represent a key factor driving the global hemoglobulin testing market. In 2018, an estimated 490 Million people around the world suffered from diabetes. The prevalence of diabetes is currently being catalysed by an increasing ageing population, poor dietary habits, sedentary lifestyles and rising levels of obesity. Patients suffering from diabetes need to undergo tests to measure blood glucose and HbA1c levels regularly, driving the demand for such tests. Moreover, factors such as favourable reimbursement of hemoglobin testing under various health insurance policies is also catalyzing the growth of the market. However, in many countries, medical insurance doesn’t fully reimburse the cost of hemoglobin testing, but with partial payment and other coverages, consumers are increasingly adopting regular and periodic tests in order to check and maintain their overall health. Furthermore, factors such as improving health infrastructure, increasing per capita expenditure on health care, rising awareness for blood-related ailments, ageing population, technological advancements, etc. are also projected to drive the global hemoglobin testing market in the coming years. Looking forward, IMARC Group expects the market to reach a value of US$ 2.8 Billion by 2024, registering a CAGR of 8.5% during 2019-2024.
Report Coverage:
Historical, Current and Future Market Trends
Market Breakup by Product Type:
Reagents and Consumables
Equipment
Market Breakup by Technology:
Chromatograph
Immunoassay
Other
Market Breakup by End-User:
Laboratories
Hospitals
Research centers
Market Breakup by Region:
North America
Europe
Asia Pacific
Middle East and Africa
Latin America
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott, Bio-Rad Laboratories, Danaher, EKF Diagnostics, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Alere, ACON Laboratories, ARKRAY, Bayer Medical Care, Daiichi Biotech, DiaSys Diagnostic Systems, Epinex Diagnostics, Erba Diagnostics, etc
Key Questions Answered in This Report:
- How has the global hemoglobin testing market performed so far and how will it perform in the coming years?
- What are the key regional markets in the global hemoglobin testing industry?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the global hemoglobin testing industry?
- What are the key driving factors and challenges in the global hemoglobin testing industry?
- What is the structure of the global hemoglobin testing industry and who are the key players?
- What is the degree of competition in the global hemoglobin testing industry?
- What are the profit margins in the global hemoglobin testing industry?
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Introduction 4.1 Overview 4.2 Key Industry Trends 5 Global Hemoglobin Testing Market 5.1 Market Overview 5.2 Market Performance 5.3 Market Breakup by Product 5.4 Market Breakup by Technology 5.5 Market Breakup by End-User 5.6 Market Breakup by Region 5.7 Market Forecast 6 Market Breakup by Product 6.1 Reagents and Consumables 6.1.1 Market Trends 6.1.2 Market Forecast 6.2 Equipment 6.2.1 Market Trends 6.2.2 Market Forecast 7 Market Breakup by Technology 7.1 Chromatograph 7.1.1 Market Trends 7.1.2 Market Forecast 7.2 Immunoassay 7.2.1 Market Trends 7.2.2 Market Forecast 7.3 Other 7.3.1 Market Trends 7.3.2 Market Forecast 8 Market Breakup by End-User 8.1 Laboratories 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Hospitals 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Research centers 8.3.1 Market Trends 8.3.2 Market Forecast 9 Market Breakup by Region 9.1 Europe 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 North America 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Asia Pacific 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Middle East and Africa 9.4.1 Market Trends 9.4.2 Market Forecast 9.5 Latin America 9.5.1 Market Trends 9.5.2 Market Forecast 10 SWOT Analysis 10.1 Overview 10.2 Strengths 10.3 Weaknesses 10.4 Opportunities 10.5 Threats 11 Value Chain Analysis 12 Porters Five Forces Analysis 12.1 Overview 12.2 Bargaining Power of Buyers 12.3 Bargaining Power of Suppliers 12.4 Degree of Competition 12.5 Threat of New Entrants 12.6 Threat of Substitutes 13 Price Analysis 14 Competitive Landscape 14.1 Market Structure 14.2 Key Players 14.3 Profiles of Key Players 14.3.1 Abbott 14.3.2 Bio-Rad Laboratories 14.3.3 Danaher 14.3.4 EKF Diagnostics 14.3.5 F. Hoffmann-La Roche 14.3.6 Siemens Healthineers 14.3.7 Thermo Fisher Scientific 14.3.8 Alere 14.3.9 ACON Laboratories 14.3.10 ARKRAY 14.3.11 Bayer Medical Care 14.3.12 Daiichi Biotech 14.3.13 DiaSys Diagnostic Systems 14.3.14 Epinex Diagnostics 14.3.15 Erba Diagnostics |
Market Breakup by Product
- Reagents and Consumables
- Equipment
Market Breakup by Technology
- Chromatograph
- Immunoassay
- Other
Market Breakup by End-User
- Laboratories
- Hospitals
- Research centers
Market Breakup by Region
- Europe
- North America
- Asia Pacific
- Middle East and Africa
- Latin America
EUROPE SPECIALTY GENERICS MARKET: INDUSTRY TRENDS, SHARE, SIZE, GROWTH, OPPORTUNITY AND FORECAST 2019-2024
| Healthcare | Published by: IMARC GROUP | Market: |
| 96 pages | Published: 04-08-2019 |
- Healthcare
- IMARC GROUP
- 96 pages
- Published: 04-08-2019
Europe specialty generics market reached a value of US$ 13.2 Billion in 2018. Specialty generics are classified as high-cost, high complexity and/or high touch generics. They are the generic versions of speciality branded drugs after they lose their patent protection. Specialty generics are used to treat complex diseases which may be chronic by nature and life-threatening like hepatitis C, cancer, rheumatoid arthritis, multiple sclerosis, etc.
Driven by factors such as an increasing aging population, changing lifestyles and a rising prevalence of chronic diseases, healthcare costs in Europe have increased significantly in recent years creating a huge burden on the government, healthcare providers and patients. Specialty generics are playing a major role in the region to reduce this cost burden as they are more cost-effective as compared to their branded versions. Unlike branded speciality drugs, specialty generics don’t require expensive and time-consuming research and development procedures. Additionally, they also don’t incur the same amount of marketing and promotional expenses, resulting in substantially lower costs. In addition to this, the patent expiration of several blockbuster specialty drugs is expected to expire in the coming years creating a positive impact on the market. Looking forward, IMARC Group expects the market value to reach US$ 21.9 Billion by 2024, exhibiting a CAGR of around 9% during 2019-2024.
Market Scope:
Historical, Current and Future Market Trends
Market Breakup by Region:
Italy
Germany
France
United Kingdom
Spain
Rest of Europe
Market Breakup by Route of Administration:
Injectables
Oral
Others
Market Breakup by Indication:
Oncology
Autoimmune Diseases
Infectious Diseases
Others
Market Breakup by Distribution Channel:
Retail Pharmacies
Specialty Pharmacies
Hospital Pharmacies
Competitive Landscape:
The leading players in the European specialty generics industry have also been examined in the report.
Key Questions Answered in This Report:
- How has the European specialty generics market performed so far and how will it perform in the coming years?
- What is the breakup of the European specialty generics market based on the region?
- What is the breakup of the European specialty generics market based on the route of administration?
- What is the breakup of the European specialty generics market based on the indication?
- What is the breakup of European specialty generics market based on the distribution channel?
- What are the various stages in the value chain of the specialty generics industry?
- What are the key driving factors and challenges in the European specialty generics market?
- What is the structure of the European specialty generics industry and who are the key players?
- What is the degree of competition in the European specialty generics market
| 1 Preface 2 Scope and Methodology 2.1 Objectives of the Study 2.2 Stakeholders 2.3 Data Sources 2.3.1 Primary Sources 2.3.2 Secondary Sources 2.4 Market Estimation 2.4.1 Bottom-Up Approach 2.4.2 Top-Down Approach 2.5 Forecasting Methodology 3 Executive Summary 4 Global Specialty Generics Market: Introduction 4.1 What are Specialty Generic Drugs? 4.2 Types of Specialty Generics 5 Why are Specialty Generics So Lucrative? 6 Global Specialty Generics Market 6.1 Market Overview 6.2 Market Performance 6.3 Market Breakup by Route of Administration 6.4 Market Breakup by Indication 6.5 Market Breakup by Distribution Channel 6.6 Market Breakup by Region 6.7 Market Forecast 7 Europe Specialty Generics Market 7.1 Market Overview 7.2 Market Performance 7.3 Market Breakup by Route of Administration 7.4 Market Breakup by Indication 7.5 Market Breakup by Distribution Channel 7.6 Market Breakup by Region 7.7 Market Forecast 7.8 SWOT Analysis 7.8.1 Overview 7.8.2 Strengths 7.8.3 Weaknesses 7.8.4 Opportunities 7.8.5 Threats 7.9 Value Chain Analysis 7.10 Porters Five Forces Analysis 7.10.1 Overview 7.10.2 Bargaining Power of Buyers 7.10.3 Bargaining Power of Suppliers 7.10.4 Degree of Competition 7.10.5 Threat of New Entrants 7.10.6 Threat of Substitutes 7.11 Key Market Drivers and Success Factors 8 Market Breakup by Route of Administration 8.1 Injectable 8.1.1 Market Trends 8.1.2 Market Forecast 8.2 Oral 8.2.1 Market Trends 8.2.2 Market Forecast 8.3 Others 8.3.1 Market Trends 8.3.1 Market Forecast 9 Market Breakup by Indication 9.1 Oncology 9.1.1 Market Trends 9.1.2 Market Forecast 9.2 Autoimmune Diseases 9.2.1 Market Trends 9.2.2 Market Forecast 9.3 Infectious Diseases 9.3.1 Market Trends 9.3.2 Market Forecast 9.4 Others 9.4.1 Market Trends 9.4.2 Market Forecast 10 Market Breakup by Distribution Channel 10.1 Retail Pharmacies 10.1.1 Market Trends 10.1.2 Market Forecast 10.2 Specialty Pharmacies 10.2.1 Market Trends 10.2.2 Market Forecast 10.3 Hospital Pharmacies 10.3.1 Market Trends 10.3.2 Market Forecast 11 Market Breakup by Region 11.1 Italy 11.1.1 Market Trends 11.1.2 Market Forecast 11.2 Germany 11.2.1 Market Trends 11.2.2 Market Forecast 11.3 France 11.3.1 Market Trends 11.3.2 Market Forecast 11.4 United Kingdom 11.4.1 Market Trends 11.4.2 Market Forecast 11.5 Spain 11.5.1 Market Trends 11.5.2 Market Forecast 11.6 Rest of Europe 11.6.1 Market Trends 11.6.2 Market Forecast 12 Competitive Landscape 12.1 Market Structure 12.2 Key Players 12.3 Profiles of Key Players |
Market Breakup by Route of Administration
- Injectable
- Oral
- Others
Market Breakup by Indication
- Oncology
- Autoimmune Diseases
- Infectious Diseases
- Others
Market Breakup by Distribution Channel
- Retail Pharmacies
- Specialty Pharmacies
- Hospital Pharmacies
Market Breakup by Region
- Italy
- Germany
- France
- United Kingdom
- Spain
- Rest of Europe